The invention relates to chemistry and medicine, namely to biologically active coordinative compounds from the class of thiosemicarbazidates of transition metals and can find application in medicine for the prevention and treatment of human myeloid leukemia.

Summary of the invention consists in that two new coordinative compounds are proposed as human myeloid leukemia HL-60 cell proliferation inhibitors: dichloro-[N-(3-methoxy-phenyl)-2-(pyridine-2-ylmethylene)-hydrazinecarbothioamide]zinc (I) and dichloro-[N-(4-methoxyphenyl)-2-(pyridine-2-ylmethylene)-hydrazinecarbothioamide]zinc (II) of the general Formula:



(I, II), wherein I: $R^1 = H$, $R^2 = OCH_3$; II: $R^1 = OCH_3$, $R^2 = H$. The proposed compounds expand the range of highly active inhibitors of human myeloid leukemia.

Claims: 2 Fig.: 1